Related references
Note: Only part of the references are listed.Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
Tyler C. Haddad et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Association between immune-related adverse event timing and treatment outcomes
David Hsiehchen et al.
ONCOIMMUNOLOGY (2022)
Prognostic significance of thrombocytosis in lung cancer: a systematic review and meta-analysis
Yunfei Ma et al.
PLATELETS (2021)
Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors
Corey C. Foster et al.
CANCER (2021)
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β
Alessandra Metelli et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial
Alexander M. M. Eggermont et al.
JAMA ONCOLOGY (2020)
Platelets disrupt vasculogenic mimicry by cancer cells
Carmela Martini et al.
SCIENTIFIC REPORTS (2020)
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai et al.
BIOMARKER RESEARCH (2020)
Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy
Hussein A. Assi et al.
FUTURE SCIENCE OA (2020)
Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis
Qingjian Ye et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2019)
Platelet count correlates with stage and predicts survival in melanoma
Saleh Rachidi et al.
PLATELETS (2019)
Role of Platelet Size Revisited-Function and Protein Composition of Large and Small Platelets
Stefan Handtke et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions
Aleksandra Korniluk et al.
MEDIATORS OF INFLAMMATION (2019)
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
Mingjia Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 Blockade
Brian P. Riesenberg et al.
JOURNAL OF IMMUNOLOGY (2019)
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: updates diagnostic hazard of autoimmunity at a distance
Marcus A. Couey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Zhenbin Qiu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Platelet Metabolism and Other Targeted Drugs; Potential impact on immunotherapy
Preeti Kanikarla-Marie et al.
FRONTIERS IN ONCOLOGY (2018)
Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis
Yi Zhuo et al.
PLATELETS (2017)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Elevated mean platelet volume predicts poor prognosis in colorectal cancer
Na Li et al.
SCIENTIFIC REPORTS (2017)
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
Marianne Davies et al.
IMMUNOTARGETS AND THERAPY (2017)
Platelets subvert T cell immunity against cancer via GARP-TGFβ axis
Saleh Rachidi et al.
SCIENCE IMMUNOLOGY (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Platelets and Inflammatory Markers in Patients with Gastric Cancer
Joanna Matowicka-Karna et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes Metastasis
Myriam Labelle et al.
CANCER CELL (2011)
Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis
S Lindemann et al.
JOURNAL OF CELL BIOLOGY (2001)
Share Paper
